Phar­ma vet­er­ans re­group with $50M and a plan to dis­cov­er new mul­ti-specifics

While a horde of drug­mak­ers de­vel­ops bis­pe­cif­ic an­ti­bod­ies to more di­rect­ly tar­get tu­mor cells — there were about 100 pro­grams in or near­ing clin­i­cal tri­als back in May — a new com­pa­ny is emerg­ing to go one step fur­ther.

On Thurs­day, Ten­tar­ix Bio­ther­a­peu­tics un­veiled a $50 mil­lion Se­ries A round to sup­port its next-gen mul­ti-specifics plat­form. While the field has large­ly fo­cused on bis­pecifics, which en­gage two tar­gets, Ten­tar­ix be­lieves its mul­ti­func­tion­al pro­grams have the po­ten­tial to be even more spe­cif­ic, since more con­di­tions must be met for po­tent ac­tiv­i­ty to oc­cur.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER